Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations
Abstract TMPRSS4, a transmembrane serine protease type II, is associated with various pathological illnesses. It has been found to activate SARS-CoV-2, enhance viral infection of human small-intestinal enterocytes and is overexpressed in different types of cancers. Therefore, this study aims to diso...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-86961-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585843373506560 |
|---|---|
| author | Ismail Hdoufane Mehdi Oubahmane Youssef Habibi Christelle Delaite Mohammed M. Alanazi Driss Cherqaoui |
| author_facet | Ismail Hdoufane Mehdi Oubahmane Youssef Habibi Christelle Delaite Mohammed M. Alanazi Driss Cherqaoui |
| author_sort | Ismail Hdoufane |
| collection | DOAJ |
| description | Abstract TMPRSS4, a transmembrane serine protease type II, is associated with various pathological illnesses. It has been found to activate SARS-CoV-2, enhance viral infection of human small-intestinal enterocytes and is overexpressed in different types of cancers. Therefore, this study aims to disover potential TMPRSS4 inhibitors that have better binding affinity than the approved inhibitors: 2-hydroxydiarylamide and tyroserleutide. Since no 3D-structure is known for TMPRSS4, structural models for the TMPRSS4 serine protease domain were developed. The modeled structures were validated and subjected to molecular dynamics simulations. FDA-approved, clinical/preclinical drugs and natural products were docked to the pocket of TMPRSS4. Moreover, through a systematic analysis, MD simulations and MM-GBSA binding free energy calculations revealed that the best candidates Ergotamine, S55746, NPC478048, Lifirafenib, and NPC77101 are highly stable drug candidates in complex with TMPRSS4, displaying low RMSD and RMSF values with strong binding stability. Among these compounds, Ergotamine showed the most favorable binding energy (-33.73 kcal/mol). Overall, our in silico results revealed that these compounds could act as potent TMPRSS4 inhibitors and need to be validated by future experimental studies. |
| format | Article |
| id | doaj-art-58240ee28b594f32972a081dba0e5793 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-58240ee28b594f32972a081dba0e57932025-01-26T12:28:34ZengNature PortfolioScientific Reports2045-23222025-01-0115111510.1038/s41598-025-86961-5Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulationsIsmail Hdoufane0Mehdi Oubahmane1Youssef Habibi2Christelle Delaite3Mohammed M. Alanazi4Driss Cherqaoui5Laboratory of Molecular Chemistry, Department of Chemistry, Faculty of Sciences Semlalia, Cadi Ayyad UniversityLaboratory of Molecular Chemistry, Department of Chemistry, Faculty of Sciences Semlalia, Cadi Ayyad UniversitySustainable Materials Research Center (SUSMAT-RC), University Mohamed VI Polytechnic (UM6P)Laboratoire de Photochimie et d’Ingénierie Macromoléculaires (LPIM EA 4567), Université de Haute-AlsaceDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud UniversityLaboratory of Molecular Chemistry, Department of Chemistry, Faculty of Sciences Semlalia, Cadi Ayyad UniversityAbstract TMPRSS4, a transmembrane serine protease type II, is associated with various pathological illnesses. It has been found to activate SARS-CoV-2, enhance viral infection of human small-intestinal enterocytes and is overexpressed in different types of cancers. Therefore, this study aims to disover potential TMPRSS4 inhibitors that have better binding affinity than the approved inhibitors: 2-hydroxydiarylamide and tyroserleutide. Since no 3D-structure is known for TMPRSS4, structural models for the TMPRSS4 serine protease domain were developed. The modeled structures were validated and subjected to molecular dynamics simulations. FDA-approved, clinical/preclinical drugs and natural products were docked to the pocket of TMPRSS4. Moreover, through a systematic analysis, MD simulations and MM-GBSA binding free energy calculations revealed that the best candidates Ergotamine, S55746, NPC478048, Lifirafenib, and NPC77101 are highly stable drug candidates in complex with TMPRSS4, displaying low RMSD and RMSF values with strong binding stability. Among these compounds, Ergotamine showed the most favorable binding energy (-33.73 kcal/mol). Overall, our in silico results revealed that these compounds could act as potent TMPRSS4 inhibitors and need to be validated by future experimental studies.https://doi.org/10.1038/s41598-025-86961-5TMPRSS4Homology modelingMolecular dynamics simulationsCancerCOVID-19 |
| spellingShingle | Ismail Hdoufane Mehdi Oubahmane Youssef Habibi Christelle Delaite Mohammed M. Alanazi Driss Cherqaoui Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations Scientific Reports TMPRSS4 Homology modeling Molecular dynamics simulations Cancer COVID-19 |
| title | Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations |
| title_full | Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations |
| title_fullStr | Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations |
| title_full_unstemmed | Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations |
| title_short | Identification of potent TMPRSS4 inhibitors through structural modeling and molecular dynamics simulations |
| title_sort | identification of potent tmprss4 inhibitors through structural modeling and molecular dynamics simulations |
| topic | TMPRSS4 Homology modeling Molecular dynamics simulations Cancer COVID-19 |
| url | https://doi.org/10.1038/s41598-025-86961-5 |
| work_keys_str_mv | AT ismailhdoufane identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations AT mehdioubahmane identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations AT youssefhabibi identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations AT christelledelaite identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations AT mohammedmalanazi identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations AT drisscherqaoui identificationofpotenttmprss4inhibitorsthroughstructuralmodelingandmoleculardynamicssimulations |